New drug aims to boost power of cancer immunotherapy
NCT ID NCT05605496
Summary
This study is testing if adding an experimental drug called NP137 to standard immunotherapy helps patients with advanced solid tumors. It focuses on people whose cancer has stopped responding well to their current immunotherapy. The goal is to see if the combination can better control the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Institut Claudius Regaud (IUCT Oncopole)
Toulouse, 31059, France
-
Institut Curie
Paris, 75005, France
-
Institut de Cancérologie Strasbourg Europe (ICANS)
Strasbourg, 67033, France
Conditions
Explore the condition pages connected to this study.